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Abstract
For over a century, nebulizers have been commonly used to deliver aerosolized medications in the treatment of patients with pulmonary diseases. 
They are the aerosol device of choice when patients can not coordinate inhalation and actuation needed for the use of the pressurized metered-dose 
inhalers (pMDIs) or are not able to provide the necessary inspiratory flow required by the dry powder inhaler (DPI) for effective aerosol drug delivery. 
Three types of nebulizers exist: (1) jet nebulizers, (2) ultrasonic nebulizers, and (3) mesh nebulizers. The purpose of this paper is to explain the types of 
nebulizers available on the market and to evaluate their efficiencies in aerosol drug delivery while suggesting strategies for the optimal treatment of 
patients with pulmonary diseases. 
Keywords: Nebulizers, aerosols, inhalation therapy
Delivery of aerosolized drugs was revolutionized in the 1950s with the development of nebulizers 
and pressurized metered-dose inhalers. Nebulizers transform liquid formulations and suspension into 
medical aerosol. In the past few years, there have been advances in the development of new nebu-
lizers that hold the promise to improve aerosol drug delivery to patients with pulmonary diseases. 
Nebulizers are divided into three categories: (1) jet nebulizers, (2) ultrasonic nebulizers, and (3) mesh 
nebulizers. While jet nebulizers are commonly used for the treatment of patients with pulmonary dis-
eases, they are bulky and require a power source. Due to aerosolized droplets and solvent vapor that 
saturates the outgoing air, jet nebulizers cool the drug solution in the nebulizer and increase solute 
concentration in the residual volume. Although ultrasonic nebulizers are more efficient and compact 
than jet nebulizers, they can not be used to deliver proteins or suspensions. With the development of 
mesh nebulizers that use lower-frequency waves, heating issues that denature proteins during aero-
sol therapy are eliminated. Also, it has been shown that mesh nebulizers are suitable for delivery of 
suspensions, liposomes, and nucleic acids (1-5). Since there is a large number of nebulizers in each 
category that have been introduced to the market, the purpose of this paper is to explain the types of 
nebulizers available and to evaluate their efficiencies in aerosol drug delivery. In addition, strategies 
for optimal inhalation treatment of patients with pulmonary diseases will be investigated.
JET NEBULIZERS 
Traditionally, jet nebulizers have been used for the treatment of pulmonary diseases. These nebulizers 
require 2 to 10 L/min of pressurized gas to draw medication up through a capillary tube from the 
nebulizer reservoir in order to generate a wide range of particle sizes that are blasted into one or more 
baffles, which take larger particles out of suspension and return them to the reservoir. 
Jet nebulizers are effective in delivering formulations that can not be delivered with pressurized 
metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). For instance, antibiotics, mucolytics, 
liposomal formulations, and recombinant products, such as Pulmozyme® Inhalation Solution, are 
some of the medications that can be delivered via jet nebulizers. On the other hand, jet nebulizers 
can be difficult to use because of their need for compressed gas and additional tubing. Also, several 
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Review
studies have proven their inefficiencies in drug delivery (6-8). For 
these reasons, new types of jet nebulizers have been developed over 
the years. Through improvements in the nebulizer design, new jet 
nebulizers either have reservoirs that conserve aerosols or utilize baf-
fles that reduce the size of large particles and increase the efficiency 
of aerosol therapy. They also have breath-enhanced aerosol produc-
tion that leads to greater drug delivery, a larger fine-particle fraction, 
and less drug loss during expiration.
Jet nebulizers are divided into four categories: (1) jet nebulizers with a 
corrugated tube, (2) jet nebulizers with a collection bag, (3) breath-en-
hanced jet nebulizers, and (4) breath-actuated jet nebulizers.
Jet Nebulizers with a Corrugated Tube
Jet nebulizers with a corrugated tube are conventional constant-out-
put nebulizers that generate continuous aerosol during inspiration, 
expiration, and breath-hold. Although the corrugated tube attached 
to the jet nebulizer acts as a reservoir, there is still significant drug 
loss during expiration with this type of nebulizer. Other disadvantag-
es of these nebulizers include limited portability, requirements for 
compressed air/gas sources for operation, and variability between 
nebulizers (9-11). While jet nebulizers with a corrugated tube have 
several disadvantages, they are easy to use and have a good profile 
on patient compliance with treatment (12). 
Jet Nebulizers with a Collection Bag
A jet nebulizer with a collection bag is considered a dosimetric nebu-
lizer that releases aerosol only during inhalation. Aerosols generated 
during expiration are stored in the collection bag and given to the 
patient with the next inspiration through a one-way valve that is lo-
cated between the mouthpiece and the collection bag. The Circulaire 
(Westmed INC, Tucson, AZ) is an example of this type of nebulizer. It 
has a better clinical profile than jet nebulizers with corrugated tub-
ing, as it improves peak expiratory flow, heart rate, and respiratory 
rate in patients admitted to the emergency department due to bron-
chospasm (13). In addition, the Circulaire decreases the amount of 
drug escaping into the environment, providing less exposure to care-
givers (14,15) while improving aerosol drug delivery to the patient’s 
lungs (14-16). 
Breath-Enhanced Jet Nebulizers
Breath-enhanced jet nebulizers release more aerosol during inhala-
tion through one-way valves in the mouthpiece. They generate aero-
sols using a negative pressure created by a patient’s inspiratory effort. 
PARI LC Plus, (PARI, Midlothian, VA) PARI LCD (PARI, Midlothian, VA), 
and NebuTech, (Salter Labs, Arvin, CA) are examples of breath-en-
hanced jet nebulizers. Although the efficiency of breath-enhanced 
nebulizers is better than jet nebulizers with corrugated tubing 
(17,18), it must be noted that not all breath-enhanced nebulizers 
have the same efficiency (19), due to differences in residual volume 
and particle size. 
Breath-Actuated Jet Nebulizers
Breath-actuated jet nebulizers (BANs), like the AeroEclipse 
(Monoghan/Trudell Medical International, London, Ontario, Canada), 
sense the patient’s inspiratory flow and deliver aerosol only on in-
spiration. Therefore, these nebulizers decrease drug wastage during 
aerosol therapy but can increase treatment time (20). The AeroE-
clipse has a green button on the top part of the nebulizer that moves 
up and down and shows the patient when the nebulizer is actuat-
ed. The actuator button moves down and starts generating aerosol 
when the patient inhales. The actuator moves back up to its closed 
position during expiration in order to stop aerosol production un-
til the patient’s next breath. Since it generates aerosol in response 
to the patient’s inspiratory maneuver, it has a low level of drug loss 
to the environment. The AeroEclipse is easy to use and is associated 
with a lower occurrence of adverse events (21). A recent clinical study 
reported that the breath-actuated nebulizer was more effective in re-
ducing lung hyperinflation and respiratory frequency in patients with 
acute exacerbation of chronic obstructive pulmonary disease (COPD) 
(22). Also, patients and respiratory therapists had greater satisfaction 
with the BAN in adult patient populations, compared to the jet neb-
ulizer with a corrugated tube (21). Although studies evaluating the 
efficiency of the breath-actuated nebulizers in pediatric patient pop-
ulations are limited, an in vitro study showed that breath-actuated 
nebulization generated a lower lung dose and higher treatment time 
in a simulated spontaneously breathing 2-4 year old child (23).
ULTRASONIC NEBULIZERS
Ultrasonic nebulizers incorporate a piezoelectric crystal vibrating 
at high frequencies (1-3 MHz) in order to produce aerosol. They are 
divided into two categories (1) large-volume ultrasonic nebulizers 
and (2) small-volume ultrasonic nebulizers. Whereas large-volume 
ultrasonic nebulizers are most commonly used to deliver hypertonic 
saline for sputum induction, small-volume ultrasonic nebulizers are 
used for delivery of inhaled medications. Ultrasonic nebulizers have 
many limitations compared to jet nebulizers. For instance, they have 
large residual volumes, an inability to aerosolize viscous solutions, 
and degradation of heat-sensitive materials. Therefore, they should 
not be used with suspensions and proteins (10,11,24,25). 
MESH NEBULIZERS
Recent improvements in nebulizer technologies have led to the 
development of mesh nebulizers using micropump technology for 
aerosol production. They force liquid medications through multiple 
apertures in a mesh or aperture plate in order to generate aerosol. 
As small and portable nebulizers that are powered by either battery 
or electricity, they have silent operation, short treatment times, in-
creased output efficiency, and minimal residual volume (9,12,26-28). 
Advantages of mesh nebulizers include consistent and improved 
aerosol generation efficiency, a predominantly fine-particle fraction 
reaching into the peripheral lung, low residual volume, and the abil-
ity to nebulize in low drug volumes. The size of the pore, the aerosol 
chamber, and the reservoir, as well as the output rate of mesh nebu-
lizers, can be adjusted for different drugs in order to optimize aerosol 
drug delivery to patients (27). Comparisons of mesh and ultrasonic 
nebulizers demonstrated similar drug delivery in simulated ventila-
tor-dependent patients (29,30). Mesh nebulizers are more efficient 
than jet nebulizers and can provide higher drug doses to patients. 
Although human studies with mesh nebulizers are limited, in vitro 
studies demonstrated approximately 2-3 times higher lung deposi-
tion with mesh nebulizers when compared to jet nebulizers (31,32). 
Due to the higher efficiency of mesh nebulizers, the dosages of drug 
formulations may need to be adjusted in order to prevent the devel-
opment of adverse effects because of overdose. Therefore, patients 
should be monitored closely during treatment for clinical responses 
and side effects.
Despite many advantages of these nebulizers, there are challenges 
associated with mesh nebulizers. For instance, delivery of viscous 
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drugs and suspensions can clog the pores, and it can be difficult to 
determine from the output of the device. Also, cleaning of mesh neb-
ulizers can be difficult. These nebulizers are also more expensive than 
jet nebulizers.
Mesh nebulizers can be classified into two categories: (1) active mesh 
nebulizers and (2) passive mesh nebulizers. Active mesh nebulizers 
use a piezo element that contracts and expands on application of an 
electric current and vibrates a precisely drilled mesh in contact with 
the medication in order to generate aerosol. Passive mesh nebulizers 
use a transducer horn that induces passive vibrations in the perfo-
rated plate with 6000 tapered holes to produce aerosol. Examples of 
active mesh nebulizers include the Aeroneb ® (Aerogen, Galway, Ire-
land) and the eFlow ® (PARI, Starnberg, Germany), while the Microair 
NE-U22 ®(Omron, Bannockburn, IL) is a passive mesh nebulizer. Each 
type of mesh nebulizer is explained in more detail below.
Active Mesh Nebulizers
Aeroneb (Aerogen, Galway, Ireland): Aeroneb nebulizers are used 
for both spontaneously breathing and ventilator-dependent pa-
tients. While the Aeroneb ®Go is a portable compact handheld neb-
ulizer, the Aeroneb ®Solo is used for aerosol delivery via invasive 
and noninvasive ventilation. The Aeroneb ®NIVO is used for aerosol 
delivery during noninvasive ventilation. All of them are assembled 
easily, have silent operation and short treatment duration, and are 
easy to clean. These features make it a more desirable nebulizer for 
patients and caregivers than jet nebulizers. Although the Aeroneb is 
a very efficient nebulizer that can administer a variety of drug formu-
lations, there are some limitations with their use. For instance, they 
are expensive nebulizers that have a finite operational life span due 
to their vibrating piezoelectric element. Precipitation and crystalliza-
tion of drug particles can clog the apertures that lead to inefficiency 
in aerosol drug delivery to patients. Also, using detergents during 
cleaning can damage the nature of the nebulizer. While the Aeroneb 
Solo and NIVO provide an airtight seal in the ventilator circuit as an 
in-line device, their controller units limit their portability, unlike the 
Aeroneb Go.
eFlow ®(PARI, Starnberg, Germany): The PARI eFlow is a battery-op-
erated, compact, portable nebulizer using the ODEM TouchSpray at-
omizing head that consists of a membrane with 4,000 laser-drilled ap-
ertures surrounded by a piezoelectric actuator to generate aerosol. It 
is a highly efficient nebulizer that provides approximately 90% of the 
nominal dose in a short treatment duration. Recent studies showed 
that the eFlow can improve patient compliance due to short nebuli-
zation time (33). Also, the eFlow has a range of optimal fill volumes 
up to 4 ml and can be used with a variety of drug formulations, such 
as highly viscous fluids, proteins, peptides, suspensions, and surfac-
tants. Nebulization with the eFlow is highly efficient at approximately 
90% of the charge dose, with aerosol output at rates up to 1 ml/min, 
which leads to a short treatment duration. Mesh nebulizers, such as 
the e-Flow, should be repeatedly washed and disinfected in order to 
prevent possible microbiological contamination with cystic fibrosis 
patients. Previous studies showed that the performance of jet nebu-
lizers was influenced by washing and disinfecting (34-36). However, 
no significant performance change in the e-Flow was found (37).
Passive Mesh Nebulizers
Microair NE-U22 (Omron, Bannockburn, IL): The Microair is a passive 
mesh nebulizer that employs mesh technology in order to provide 
efficient aerosol drug delivery with a predominantly fine-particle 
fraction. Just like other mesh nebulizers, it does not cause the de-
naturation or inactivation typically associated with the shear forces 
or reservoir heat generated with jet or ultrasonic nebulizers (12). 
However, there are potential problems with the MicroAir. It is an 
expensive nebulizer and hard to clean, as it has to be disassembled 
and cleaned after each use in order to prevent clogging of the mesh 
apertures. The treatment time may be shortened if concentrated 
solutions are used for therapy. Position of the Omron mesh nebulizer 
influences treatment time and variability in particle distribution (38). 
Although drug delivery with the Omron was greater in the horizontal 
position than the tilted position, its aerosol deposition was similar to 
a jet nebulizer (38). 
Smart Nebulizers
Smart nebulizers employ adaptive aerosol delivery (AAD®) technol-
ogy, which analyzes the patient’s breathing pattern in order to de-
termine the timing of aerosol drug delivery during inhalation. They 
analyze pressure changes of the airflow during the first 3 breaths to 
determine the correct starting point for drug delivery. Then, the de-
vice continues to monitor the preceding 3 breaths throughout the 
treatment and adapts to the patient’s breathing pattern. This adapta-
tion reduces not only losses of aerosol during expiration but also the 
variation in drug delivery during inhalation therapy while improving 
patient adherence to treatment (39-41). Smart nebulizers also pro-
vide the patient with feedback about their effectiveness in using the 
device during therapy. Once the preset dose has been delivered to 
the patient, the device turns off and a buzzer indicates completion 
of treatment. There are a variety of new formulations for pulmonary 
delivery available on the market, and the need for better control over 
delivered doses of expensive drugs becomes particularly important, 
because continuous jet nebulizers waste 60-70% of a dose during 
exhalation. Also, breathing patterns impact drug deposition in the 
lung. For instance, nebulization at the end of inspiration will most 
likely not reach the lung. Therefore, it is important to adapt aerosol 
drug delivery based on patients’ breathing patterns using smart 
nebulizers, such as the I-neb (Philips Respironics, Newark, USA) and 
AKITA (Activaero, Gemunden/Wohra, Germany). Thus, more accurate 
and reproducible drug delivery to patients with pulmonary diseases 
may be achieved.
I-neb (Philips Respironics, Newark, USA): The I-neb adaptive aero-
sol delivery (AAD®) nebulizer (Philips Respironics, Newark, USA) is a 
small, lightweight, battery-powered, and silent smart nebulizer that 
combines mesh technology with AAD® technology in order to deliv-
er a precise, reproducible dose. The I-neb AAD® uses multiple-breath 
technology that is programmed with the inhalation dose. Through 
AAD technology, the timing of aerosol delivery is determined based 
on the patient’s breathing pattern in order to improve the precision 
and reproducibility of dosing. In other words, a computer that is used 
with these technologies learns how the patient is breathing and 
adapts to changes in this breathing pattern, averaged over a series of 
breaths. The I-neb monitors peak flow of a patient’s first three inhala-
tions in order to determine the duration of aerosol production need-
ed to target the beginning of a breath. Since the nebulizer produces 
aerosols only during the first half of inspiration, aerosols navigate the 
bronchial tree and reach the deep lung. Patients using these nebu-
lizers receive feedback when the dose is delivered. Also, the device 
creates a data logger that acts as an electronic diary to help clinicians 
assess patient adherence. The dose-metering chamber has a low 
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residual volume and comes in various sizes to accommodate the 
dose requirements of different drug formulations.
The I-neb has two different breathing patterns: (1) the tidal breathing 
mode (TBM) and (2) the target inhalation mode (TIM). In the TBM, the 
device continuously monitors the patient’s breathing pattern and 
adapts any changes based on the average. Then, the device delivers 
aerosolized medication in the first 50% to 80% of inspiration in or-
der to minimize the amount of drug wasted during exhalation. In the 
TBM mode, the device has no control over a patient’s breathing pat-
tern. The patient decides how fast or slow she/he is going to breathe. 
However, in the TIM, the device guides patients to take a slow and 
deep breath through a tactile stimulus, coaching them to inhale very 
slowly based on their capability (41).
The I-neb AAD system improves inhaled alpha1-antitrypsin delivery 
through inspiration-only aerosol delivery and low residual volume. 
Slow, deep, and controlled inspirations using the I-neb AAD sys-
tem is an efficient method to deliver inhaled alpha1-antitrypsin for 
treatment of cystic fibrosis to protect the lungs from excessive free 
elastase (42). Previous research indicates increased ease of use and 
more satisfaction with the I-neb AAD system than with other nebu-
lizers available on the market, and it was also shown that the I-neb 
AAD system significantly improves dyspnea and fatigue in patients 
with chronic obstructive pulmonary disease compared to other neb-
ulizers (42). Aerosol deposition with slow and deep inhalation in the 
TIM was significantly superior to drug delivery achieved during tidal 
breathing in the TBM. However, the nebulization time in the TIM is 
shorter than in the TBM (43). 
The AKITA (Activaero, Gemunden/Wohra, Germany): The AKITA is a 
breath-actuated nebulizer that has no aerosol production on exha-
lation. It can be combined with a standard jet or mesh nebulizer for 
pulmonary delivery. The AKITA nebulizer individualizes patient aero-
sol delivery using a computer algorithm and personal “Smart Cards” 
that calibrate the device and track patient adherence to therapy (44). 
Through controlled breathing, the AKITA provides appropriate dos-
ing that results in high efficiency and low variability in aerosol drug 
delivery to patients with pulmonary diseases. Despite the advantag-
es of the AKITA in aerosol drug delivery, it is important to note that 
the AKITA is a large, less portable nebulizer that has a long treatment 
time. Also, there is not enough evidence about its use in infants and 
children with pulmonary diseases.
OPTIMUM USE OF NEBULIZERS IN CLINICAL PRACTICE
There are many factors affecting aerosol drug delivery to patients 
with pulmonary delivery. Successful inhalation therapy is tech-
nique-dependent. Therefore, clinicians need to know the different 
types of nebulizers available for aerosol therapy, the optimum tech-
nique that needs to be used in clinical practice, and troubleshooting 
with each type of nebulizer. Table 1 explains the advantages and dis-
advantages of different types of nebulizers.
It must be noted that the gas flow and pressure used with jet neb-
ulizers impact particle size and drug delivery. For instance, each jet 
nebulizer has a specific flow rate requirement, ranging from 2-10 L/
min, that was determined by the manufacturer and listed on the de-
vice label. Failure to set the flow meter appropriately will produce 
large particles during aerosol therapy. Sometimes, clinicians prefer to 
use a compressor along with a jet nebulizer. However, it is important 
to know that jet nebulizers are designed to operate at 50 psi and that 
the use of a compressor producing 13 psi will increase particle size 
and decrease efficiency of the treatment. Therefore, jet nebulizers 
should either be used with compressors that match their intended 
designs or be operated with a flow rate that is recommended on the 
device label by the manufacturer. 
While jet nebulizers are operated with either compressed air or oxy-
gen, using a helium/oxygen mixture (heliox) with jet nebulizers has 
become popular in recent years, as delivering aerosol with heliox im-
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Nebulizers Advantages Disadvantages
Jet nebulizers with corrugated tubing • Cheap • Inefficient
 • Easy to use • Difficult to clean
 • Effective in delivering drugs that can  • Need compressed 
   not be delivered with pMDIs and DPIs   gas and additional tubing
Breath-actuated & Breath-enhanced  • Drug delivery only during inhalation • Need sufficient flow to trigger drug delivery
jet nebulizers   • Easy to use • Takes longer to deliver  drug
 • Less medication wasted • Not ventilator-enabled
 • More efficient than JNs with tubing • More expensive
Ultrasonic nebulizers • Easy to use • Large residual volume
 • More efficient than jet nebulizers • Inability to aerosolize viscous solutions
  • Degradation of heat-sensitive materials
Mesh nebulizers • Fast, quiet, portable • More expensive
 • Self-contained power source • Cleaning can be difficult
 • Optimize particle size for specific drugs • Medication dosage must be adjusted in  
 • More efficient than other nebulizers   transition from JNs 
 • Easy to use • Not compatible with viscous liquids or  
    those that crystallize on drying
JNs: Jet nebulizers; pMDIs: pressurized metered-dose inhalers
Table 1. Advantages and disadvantages of different types of nebulizers
proves drug delivery up to 50% (45-48). Using the right flow rate with 
heliox-driven aerosol therapy is essential for optimum aerosol drug 
delivery. For instance, if heliox is used at the same flow rate as with 
air or oxygen, the particle size and aerosol output delivered by the jet 
nebulizer will be reduced due to the low density of heliox compared 
to air and oxygen. Therefore, the flow with heliox should be increased 
by 1.5-2 times to optimize aerosol drug delivery in patients with pul-
monary diseases (48,49).
Since jet nebulizers have large residual volumes of 0.5 to 2 mL and do 
not aerosolize below residual volume, they do not function well with 
small fill volumes, such as 2 mL or less. Therefore, clinicians should con-
sider increasing the fill volume to improve the efficiency of jet neb-
ulizers. Unless the nebulizer is specifically designed for a smaller fill 
volume, the use of a fill volume of 4-5 mL with jet nebulizers is recom-
mended (6). Increasing the fill volume will dilute the medication and 
deliver a greater proportion of the dose. The only drawback of addi-
tional fill volume is the increase in treatment time with jet nebulizers.
Aerosolized drugs are administered using either a mouthpiece or a 
face mask. Although, the mouthpiece is the ideal interface to be used 
during aerosol therapy, it can not be used in infants, small children, 
and elderly who have cognitive problems. The face mask is the pre-
ferred interface in these cases, but use of a face mask increases the 
amount of aerosol deposited on the face, in the eyes, and into the 
nose. Also, it is important to achieve a good face mask seal for opti-
mum drug delivery during aerosol therapy. Since optimum aerosol 
drug delivery is technique-dependent, it is important to instruct the 
patient to do tidal breathing through the mouth with periodic deep 
breaths during aerosol therapy. Table 2 describes the optimum tech-
niques that should be used with jet, mesh, and ultrasonic nebulizers 
for aerosol drug delivery to patients with pulmonary diseases. Also, 
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Optimum technique for jet nebulizers Optimum technique for ultrasonic, mesh, & smart nebulizers
Correctly assemble the nebulizer. Correctly assemble the nebulizer.
Attach the appropriate interface (mouthpiece or mask)  Attach the appropriate interface (mouthpiece or mask) 
to the nebulizer. to the nebulizer.
Put medicine into the nebulizer cup. Do not exceed the volume  If applicable, follow manufacturer’s instructions in performing 
recommended by the manufacturer. a functionality test prior to the first use of a new nebulizer as  
 well as after each disinfection to verify proper operation.
Sit in an upright position. Put medicine into the nebulizer cup. Do not exceed the  
 volume recommended by the manufacturer.
Connect the nebulizer to a power source. Sit in an upright position.
Breathe normally with occasional deep breaths until sputter occurs  Turn on the power. 
or until the end of nebulization. 
Keep the nebulizer vertical during treatment. Follow the instructions for breathing technique that are  
 recommended by the manufacturer.
If the treatment must be interrupted, turn off the flow meter  If the treatment must be interrupted, turn off the 
to avoid waste. unit to avoid waste.
Rinse the nebulizer with sterile or distilled water and allow to air dry. At the completion of the treatment, disassemble and clean as  
 recommended by the manufacturer. Do not touch the mesh  
 during cleaning in order to prevent damage. 
Table 2. Technique for jet, ultrasonic, and mesh nebulizers
Problems Causes Solutions
Absent or low aerosol with jet Loose or unattached connections. Check the connections and make sure that  
nebulizers  they are properly attached.
 Inappropriate flow meter setting. Check the flow meter setting and adjust the  
  flow accordingly.
 Obstruction in the orifice of the jet  Check the orifice of the jet nebulizer and 
 nebulizer. clear obstructions when needed.
The unit of mesh or ultrasonic  Incorrect battery installation Check the battery installation and reinstall,
nebulizers does not operate   if needed.
 Disconnection in external power source. Check the connection with the AC adapter  
  and the electrical output.
 Overheated unit. Turn off the unit, wait until it cools down and  
  restart the unit.
 Malfunctioning electronics. Replace the unit.
Table 3. Problems, causes, and solutions during aerosol drug delivery with jet, ultrasonic, and mesh nebulizers
clinicians should be aware of potential problems that may occur with 
the use of each nebulizer during aerosol therapy. They should know 
what the underlying causes of each problem are and how to solve 
them. Table 3 explains the problems, causes, and solutions during 
aerosol drug delivery with jet, ultrasonic, and mesh nebulizers.
In conclusion, aerosol therapy via nebulizers is a well-established 
method for treatment of patients with pulmonary diseases. Recent 
advances in the development of nebulizers have made drug deliv-
ery more precise, less wasteful, and potentially much easier to use 
during inhalation therapy. Also, new types of nebulizers have yield-
ed a number of improvements, such as compact design, portability, 
shorter treatment duration, and quiet operation, that are expected 
to improve patient adherence to therapy. However, despite develop-
ments in aerosol technologies, there is still a need to reduce the costs 
of these new nebulizers.
Peer-review: Internally peer-reviewed. 
Acknowledgements: I would like to thank Dr. Benan Çağlayan, Dr. Gülderen 
Şahin and all members of the Inhalation Treatments Working Group for their 
support in writing this manuscript. 
Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The author declared that this study has received no fi-
nancial support. 
REFERENCES
1. Yoshiyama Y, Yazaki T, Arai M, Asai K, Kanke M. The nebulization of 
budesonide suspensions by a newly designed mesh nebulizer. Respira-
tory Drug Delivery 2002; VIII: 487-9. 
2. Elhissi A, Karnam KK, Danesh-Azari MR, Gill HS, Taylor KM. Formulations 
generated from ethanol-based proliposomes for delivery via medical 
nebulizers. J Pharm Pharmacol 2006; 58: 887-94. [CrossRef]
3. Elhissi A, Taylor K. Delivery of liposomes generated from proliposomes 
using air-jet, ultrasonic and vibrating mesh nebulizers. J Drug Del Sci 
Tech 2005; 15: 261-5.
4. Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/
Zn-SOD with a novel vibrating membrane nebulizer. J Liposome Res 
2006; 16: 113-25. [CrossRef]
5. Lentz YK, Anchordoguy TJ, Lengsfeld CS. Rationale for the selection of an aerosol 
delivery system for gene delivery. J Aerosol Med 2006; 19: 372-84. [CrossRef]
6. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebuliz-
er performance. Effects of diluent volume, nebulizer flow, and nebulizer 
brand. Chest 1996; 110: 498-505. [CrossRef]
7. Zainudin B, Biddiscombe M, Tolfree SE, Short M, Spiro SG. Comparison 
of bronchodilator responses and deposition patterns of salbutamol in-
haled from a pressurised metered dose inhaler, as a dry powder, and as a 
nebulised solution. Thorax 1990; 45: 469. [CrossRef]
8. Smith EC, Denyer J, Kendrick AH. Comparison of twenty three nebu-
lizer/compressor combinations for domiciliary use. Eur Repir J 1995; 8: 
1214-21. [CrossRef]
9. Ari A, Hess D, Myers TR, Rau JL. A guide to aerosol delivery devices for 
respiratory therapists. 2nd ed. Dallas, Texas: American Association for Re-
spiratory Care; 2009.
10. Ari A, Fink J Guidelines for aerosol devices in infants, children and adults: 
which to choose, why and how to achieve effective aerosol therapy? Ex-
pert Rev Respir Med 2011; 5: 561-72. [CrossRef]
11. Ari A, Restrepo RD, American Association for Respiratory Care. Aerosol 
delivery device selection for spontaneously breathing patients: 2012. 
Respir Care 2012; 57: 613-26. [CrossRef]
12. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating 
mesh/aperture plate technologies for aerosol generation. Curr Drug De-
liv 2008; 5: 114-9. [CrossRef]
13. Hoffman L, Smithline H. Comparison of Circulaire to conventional small 
volume nebulizer for the treatment of bronchospasm in the emergency 
department. Respir Care 1997; 42: 1170-4.
14. Mason J, Miller W, Small S. Comparison of aerosol delivery via Circulaire 
system vs conventional small volume nebulizer. Respir Care 1994; 39: 
1157-61.
15. Mason J, Miller W. Comparison of aerosol delivery via Circulaire nebulizer 
system versus a disposable nebulizer in COPD patients. Respir Care 1996; 
41: 1006-8.
16. Piper SD. In vitro comparison of the circulaire and Aero Tee to a tradition-
al nebulizer T-piece with corrugated tubing. Respir Care 2000; 45: 313-9.
17. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A 
comparison of the availability of tobramycin for inhalation from vented 
vs unvented nebulizers. Chest 1998; 113: 951-6. [CrossRef]
18. Dennis J. Drug nebulizer design and performance: breath enhanced jet 
versus ultrasonic. J Aerosol Med 1995; 8: 277-80. [CrossRef]
19. Ho SL, Kwong WT, O’Drowsky L, Coates AL. Evaluation of four breath-en-
hanced nebulizers for home use. J Aerosol Med 2001; 14: 467-75. [CrossRef]
20. Rau JL, Ari A, Restrepo RD. Performance comparison of nebulizer de-
signs: constant-output, breath-enhanced, and dosimetric. Respiratory 
Care 2004; 49: 174-9.
21. Arunthari V, Bruinsma RS, Lee AS, Johnson MM. A prospective, compara-
tive trial of standard and breath-actuated nebulizer: efficacy, safety, and 
satisfaction. Respir Care 2012; 57: 1242-7. [CrossRef]
22. Haynes J. Randomized controlled trial of a breath-activated nebulizer 
in patients with exacerbation of COPD. Respir Care 2012; 57: 1385-90. 
[CrossRef]
23. Lin HL, Wan GH, Chen YH, Fink JB, Liu WQ, Liu KY. Influence of nebuliz-
er type with different pediatric aerosol masks on drug deposition in a 
model of a spontaneously breathing small child. Respir Care 2012; 57: 
1894-900. [CrossRef]
24. Watts AB, McConville JT, Williams RO 3rd. Current therapies and techno-
logical advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm 
2008; 34: 913-22. [CrossRef]
25. Taylor K. Ultrasonic nebulizers for pulmonary drug delivery. Int J 
Pharm1997; 153: 93-104. [CrossRef]
26. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 
2005; 50: 367-82.
27. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple ap-
ertures to generate aerosol. Respir Care 2002; 47: 1406-16.
28. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device 
design and clinical use. Lancet 2010; 377: 1032-45. [CrossRef]
29. Pedersen K, Handlos V, Heslet L, Kristensen H. Factors influencing the in 
vitro deposition of tobramycin aerosol: a comparison of an ultrasonic 
nebulizer and a high-frequency vibrating mesh nebulizer. J Aerosol Med 
2006; 19: 175-83. [CrossRef]
30. Ari A, Areabi H, Fink JB. Evaluation of aerosol generator devices at 3 loca-
tions in humidified and non-humidified circuits during adult mechanical 
ventilation. Respir Care 2010; 55: 837-44.
31. Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence 
of nebulizer type, position, and bias flow on aerosol drug delivery in sim-
ulated pediatric and adult lung models during mechanical ventilation. 
Respir Care 2010; 55: 845-51.
32. Vecellio L, De Gersem R, Le Guellec S, Reychler G, Pitance L, Le Pennec D, 
Diot P, Chantrel G, Bonfils P, Jamar F. Deposition of aerosols delivered by 
nasal route with jet and mesh nebulizers. Int J Pharm2011; 407: 87-94. 
[CrossRef]
33. Lenney W, Edenborough F, Kho P, Kovarik JM. Lung deposition of inhaled 
tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic 
fibrosis subjects. J Cyst Fibros 2011; 10: 9-14. [CrossRef]
34. Standaert TA, Morlin GL, Williams-Warren J, Joy P, Pepe MS, Weber A, Ram-
sey BW. Effects of repetitive use and cleaning techniques of disposable jet 
nebulizers on aerosol generation. Chest 1998; 114: 577-86. [CrossRef]
Eurasian J Pulmonol 2014; 16: 1-7Arı A. Jet, Ultrasonic, and Mesh Nebulizers
6
35. Rosenfeld M, Joy P, Nguyen C, Krzewinski J, Burns J. Cleaning home 
nebulizers used by patients with cystic fibrosis: is rinsing with tap water 
enough? J Hosp Infect 2001; 49: 229-30. [CrossRef]
36. Tay ET, Needleman JP, Avner JR. Nebulizer and spacer device mainte-
nance in children with asthma. J Asthma 2009; 46: 153-5. [CrossRef]
37. Bakuridze L, Andrieu V, Dupont C, Dubus JC. Does repeated disinfection 
of the e-Flow rapid nebulizer affect in vitro performance? J Cyst Fibrosis 
2007; 6: 309-10. [CrossRef]
38. Skaria S, Smaldone GC. Omron NE U22: Comparison between vibrating 
mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010; 23: 173-80. 
[CrossRef]
39. Nikander K. Adaptive aerosol delivery: the principles. Eur Respir Rev 
1997; 7: 385-7. 
40. Denyer J. Adaptive aerosol delivery in practise. Eur Respir Rev 1997; 7: 388-9.
41. Denyer J, Nikander K, Smith NJ. Adaptive aerosol delivery (AAD) technol-
ogy. Expert Opin Drug Deliv 2004; 1: 165. [CrossRef]
42. Geller DE, Kesser KC. The I-neb adaptive aerosol delivery system enhanc-
es delivery of alpha1-antitrypsin with controlled inhalation. J Aerosol 
Med Pulm Drug Deliv 2010; 1: 55-9.
43. Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Mode of breath-
ing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery 
(AAD) system affects lung deposition of (99m)Tc-DTPA. J Aerosol Med 
Pulm Drug Deliv 2010; 1: 37-43.
44. Rubin BK. Pediatric aerosol therapy: new devices and new drugs. Respir 
Care 2011; 56: 1411-21. [CrossRef]
45. Ari A, Harwood R, Sheard M, Dailey P, Fink JB. In vitro comparison of he-
liox and oxygen in aerosol delivery using pediatric high flow nasal can-
nula. Pediatr Pulmonol 2011; 46: 795-801. [CrossRef]
46. Ari A, Fink J. Aerosol drug delivery administration with helium-oxygen 
(heliox) mixtures: an overview. Current Respiratory Medicine Reviews 
2010; 6: 80-5. [CrossRef]
47. Corcoran TE, Gamard S. Development of aerosol drug delivery with heli-
um oxygen gas mixtures. J Aerosol Med 2004; 17: 299-309. [CrossRef]
48. Fink JB. Opportunities and risks of using heliox in your clinical practice. 
Respir Care 2006; 51: 651-60.
49. Hess DR, Acosta FL, Ritz RH, Kacmarek RM, Camargo CA Jr. The effect of 
heliox on nebulizer function using a beta-agonist bronchodilator. Chest 
1999; 115: 184-9. [CrossRef]
Eurasian J Pulmonol 2014; 16: 1-7 Arı A. Jet, Ultrasonic, and Mesh Nebulizers
7
